SEC Form 4 · accession 0001209191-18-063552
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 5:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 27, 2018 | G | 589 | $0.00 | D | 57,068 | D | |
| Common StockF2,F3,F4 | Dec 17, 2018 | S | 7,707 | $65.8472 | D | 159,275 | I | Held by the Popovits 2010 Trust |
| Common StockF2,F3,F5 | Dec 17, 2018 | S | 9,079 | $66.7849 | D | 150,196 | I | Held by the Popovits 2010 Trust |
| Common StockF2,F3,F6 | Dec 17, 2018 | S | 7,014 | $67.8905 | D | 143,182 | I | Held by the Popovits 2010 Trust |
| Common StockF2,F3,F7 | Dec 17, 2018 | S | 1,200 | $68.5276 | D | 141,982 | I | Held by the Popovits 2010 Trust |
| Common StockF2,F3,F8 | Dec 18, 2018 | S | 4,070 | $65.7865 | D | 137,912 | I | Held by the Popovits 2010 Trust |
| Common StockF2,F3,F9 | Dec 18, 2018 | S | 17,208 | $66.7383 | D | 120,704 | I | Held by the Popovits 2010 Trust |
| Common StockF2,F3,F10 | Dec 18, 2018 | S | 3,722 | $67.4642 | D | 116,982 | I | Held by the Popovits 2010 Trust |
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F10Represents weighted average sale price. Actual sale prices ranged from $67.16 to $67.87.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $65.32 to $66.30.
- F5Represents weighted average sale price. Actual sale prices ranged from $66.34 to $67.315.
- F6Represents weighted average sale price. Actual sale prices ranged from $67.36 to $68.34.
- F7Represents weighted average sale price. Actual sale prices ranged from $68.365 to $68.90.
- F8Represents weighted average sale price. Actual sale prices ranged from $65.16 to $66.14.
- F9Represents weighted average sale price. Actual sale prices ranged from $66.16 to $67.15.